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clude patients with early-stage disease in immunotherapy 
trials, as immunoediting of the tumor and immune escape 
may be less pronounced.  Copyright © 2010 S. Karger AG, Basel 
 Immunological Control of Cancer 
 Burnet, Thomas and Medawar put forward the con-
cept of cancer immunosurveillance in the late 1950s. 
They postulated that the immune system recognizes 
transformed self, i.e. tumor cells that had undergone ge-
netic aberrations significant enough to result in recogni-
tion by immune cells  [1] . Several lines of evidence derived 
from murine tumor models, as well as from clinical data, 
support this concept. Today, cancer immunosurveillance 
or cancer immunoediting is thought to follow three phas-
es: an early elimination phase, followed by an equilibrium 
phase where the immune system selects variants that may 
survive immune attacks, and an immune escape phase of 
cancer cell variants that may have altered their geno- or 
antigenic phenotype or may have come under the control 
of immunoregulatory phenomena. These three phases 
can occur simultaneously at different tumor sites, and 
not all three phases must occur during the interaction 
between tumor cells and the immune system  [2–4] .
 Recent evidence obtained with methylcholanthrene-
induced sarcomas in mice shows that the elimination and 
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equilibrium phases are accomplished via the adaptive 
immune compartment: Depletion of T cells from or 
blockade of IFN (interferon)-  in apparently tumor-free 
immunocompetent mice resulted in rapid outgrowth of 
clinically occult tumors, which shows that T cells and 
IFN-  are instrumental in keeping occult tumors under 
control  [5] . Additionally, in cancer patients there is ample 
evidence for immunological control of tumors. First, tu-
mor-specific immunity can be detected in a proportion 
of cancer patients  [6] . Second, the risk of developing a tu-
mor greatly increases in immunocompromised patients, 
such as AIDS patients or organ transplant recipients. 
Third, correlative studies indicate that the presence of tu-
mor-infiltrating lymphocytes may be associated with im-
proved clinical outcome in several cancers including mel-
anoma, colorectal, breast, prostate, renal cell, esophageal 
and ovarian carcinomas  [7–13] . In particular, recent data 
in epithelial ovarian cancer indicated significant differ-
ences in the distributions of progression-free survival 
and overall survival according to the presence or absence 
of intratumoral T cells. The five-year overall survival rate 
was 38.0% among patients whose tumors contained T 
cells and 4.5% among patients whose tumors did not. In 
addition, ovarian cancer patients, whose tumors are in-
filtrated by CD4+CD25+FoxP3+ regulatory T cells (T reg ), 
demonstrated reduced survival  [14] . Fourth, after trans-
planting kidneys from a patient who died of a stroke and 
was supposedly cured of an early stage melanoma 16 
years back to two independent recipients, both recipients 
developed donor-derived metastatic melanoma under 
immunosuppressive treatment  [15] .
 Tumors escape destruction by the immune system via 
a variety of active, regulatory mechanisms. These include 
downregulation of major histocompatibility complex 
(MHC) molecules and/or the immunologically targeted 
antigens by the tumor cells, stimulation of inhibitory
receptors such as cytotoxic T lymphocyte antigen-4 
(CTLA-4) or PD-1 on T cells, induction of increased tu-
mor infiltration by regulatory CD4+CD25+FoxP3+ T 
cells (T reg ), or the production of immunosuppressive me-
diators such as IL-10, TGF-  , indoleamine 2,3-dioxyge-
nase by the tumor cells, stroma or infiltrate  [2] . The often 
patchy expression of MHC molecules and tumor-associ-
ated antigens in tumor biopsies is indicative of the dy-
namic process of tumor escape, and it was observed in 
some clinical vaccination studies that the new metasta-
ses, which developed after initial clinical response, lost 
expression of MHC class I or of the targeted antigen.
 CTLA-4 is one of the crucial negative regulators of the 
adaptive immune response and it is known now that 
CTLA-4 has a central role in the induction and mainte-
nance of peripheral T cell tolerance. This is illustrated by 
the fact that mice lacking CTLA-4 die of generalized au-
toimmunity and inflammation at the age of 3 weeks  [16] . 
It is thought that peripheral T cell tolerance occurs in 
cancer patients as a result of chronic and suboptimal an-
tigen stimulation and of the self-nature of many tumor-
associated antigens and that this limits T cell-mediated 
anti-tumor effector responses. For this reason, the thera-
peutic effect of CTLA-4 blocking antibodies was tested in 
mouse models and cancer patients, and showed encour-
aging results. Currently, clinical studies are being per-
formed in which anti-CTLA-4 treatment is combined 
with simultaneous immunization, which is expected to 
have a higher efficacy than CTLA-4 blockade alone. PD-1 
is another molecule that is expressed on T cells and is in-
volved in induction and maintenance of peripheral T cell 
tolerance. There is evidence that the ligands for PD-1, 
PD-L1 and PD-L2 are expressed by a proportion of tumor 
cells, and the first clinical studies in which cancer pa-
tients receive treatment with monoclonal antibodies that 
block PD-1 are being performed at present.
 CD4+CD25+FoxP3+ T reg are crucial in preventing 
immune responses to self-antigens. They do this by inter-
fering with the maturation of dendritic cells and by di-
rectly suppressing effector T cells (T eff ) through cell-cell 
interactions and/or soluble factors, including CTLA-4, 
IL-10 and TGF-  . The percentage of T reg in the periph-
eral blood of healthy individuals and cancer patients is 
similar and is 2–5% of CD4+ cells. In tumors, however, 
this percentage is often dramatically increased, such that 
the ratio of T eff to T reg is low. Retrospective analysis in pa-
tients with ovarian carcinoma showed a correlation be-
tween the T eff to T reg ratio and survival time, with a low 
ratio being a poor prognostic factor  [17] . Patients with 
prostate cancer who were treated with anti-CTLA-4 and 
had a clinical response showed an increase in the T eff to 
T reg ratio in some cases. In addition, T reg depletion in dif-
ferent mouse models for cancer resulted in better tumor-
specific T cell responses and a better control of tumors 
 [18] .
 Antigen Discovery and Classes of Tumor-Associated 
Antigens 
 The era of modern cancer immunology started with 
observations made in two patients (SK-29 and MZ-2) 
with recurrent metastatic melanoma, who have been ob-
served since 1978 and 1982, respectively. Both patients 
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received intradermal immunizations with irradiated au-
tologous tumor cells for an extended period of time and 
complete regression of tumor manifestations in the pres-
ence of T cell responses and strong increasing T cell re-
sponses under vaccination was documented. The pa-
tients, still alive, have remained free of disease ever since 
(for more than 2 decades now). Based on this favorable 
clinical effect, a systematic search was initiated to iden-
tify and characterize the cancer antigens and immune 
effector mechanisms that mediate tumor regression and 
tumor control in vivo. A few years later, the first reports 
on spontaneous tumor-specific T cell responses were 
published  [19] . Thierry Boon and colleagues cloned the 
first T cell-defined human cancer antigens from these 
patients in 1991: MAGE-1, tyrosinase and Melan-A. Since 
the initial reports by Boon and colleagues  [20] , a large 
number of tumor-associated antigens have been identi-
fied using similar approaches, e.g. BAGE, GAGE, and 
many others.
 Some antigens were identified by serological analysis 
of recombinant cDNA expression libraries (SEREX): 
here, an expression library is incubated with patient se-
rum, the cDNA clones that are recognized by the serum 
IgG are isolated, and the recognized protein is cloned and 
identified  [21] . Examples of tumor-associated antigens 
that were identified by SEREX are SSX, NY-ESO-1, CT7, 
Rab38, NY-CO-58 and NY-BR-1.
 Besides SEREX- and T cell-defined antigens, some an-
tigens were discovered by cancer-induced antibodies. 
Typically, these antigens are (over)expressed on the sur-
face of cancer cells and include gp75/TRP-1, p96 and 
Her2/neu.
 Nowadays, tumor-associated antigens are classified 
into one of the following categories: (1) cancer-testis (CT) 
antigens, restricted expression in germ cells and cancer 
cells, e.g. MAGE, NY-ESO-1 and LAGE-1; (2) differentia-
tion antigens, restricted to defined lineages like mela-
nocytes, e.g. tyrosinase, Melan-A/MART-1 and gp 100; 
(3) mutated antigens, altered forms of constitutive pro-
teins, e.g. CDK4,   -catenin, caspase-8 and p53; (4) ampli-
fication antigens, e.g. overexpressed Her2/neu and p53; 
(5) splice variant antigens, e.g. NY-CO-37/PDZ-45 and 
ING1; (6) glycolipid antigens; (7) viral antigens, e.g. HPV, 
EBV.
 Among all tumor antigens identified to date, the CT 
antigens are a distinct and unique class of differentiation 
antigens. The genes encoding CT antigens are frequently 
located on the X chromosome and are often members of 
multi-gene families. Furthermore, 10% of all genes on the 
X chromosome are CT antigens  [22] . CT antigens are not 
expressed in healthy tissues, except germ cells, but are 
expressed by a proportion of different tumor types in a 
lineage-nonspecific fashion. Often, a particular tumor 
expresses more than one CT antigen. The frequency of 
CT antigen expression in many cancer types ranges from 
5–40%, with exceptionally high expression of individual 
CT antigens in certain cancers, e.g. high expression of 
MAGE-C1/CT7 in myeloma and NY-ESO-1 in 80% of sy-
novial sarcoma  [23, 24] . The function of CT antigens in 
germ cells and malignant cells is largely unknown. How 
their expression is regulated is also not known at present, 
but recent evidence suggests that epigenetic events, in-
cluding DNA methylation and histone deacetylation, 
play a role. Some well-characterized members of the CT 
antigen family include MAGE, GAGE/PAGE/XAGE, 
NY-ESO-1/LAGE-1, SSX, SPANX, TRAG-3, BAGE, SCP-
1, OY-TES-1 and CT10  [22, 25] .
 Integrated Immune Responses in Cancer Patients: 
The NY-ESO-1 Paradigm 
 NY-ESO-1 was initially identified by SEREX in New 
York from a patient with esophageal cancer, hence its 
name. NY-ESO-1 is a protein of 180 amino acids with a 
molecular weight of approximately 18 kDa, and its coding 
gene is located on the X chromosome (Xq28)  [21] . The 
expression of NY-ESO-1 in healthy tissue is restricted to 
testicular germ cells, fetal ovary germ cells and tropho-
blastic epithelia of placental villi, all of which are MHC 
class I-negative. NY-ESO-1 is expressed at a variable fre-
quency in several tumor types ( fig. 1 ) and is considered 
to be the most immunogenic CT antigen to date. It elicits 
both cellular and humoral immune responses in a high 
proportion of patients with NY-ESO-1-expressing tu-
mors  [26] . These spontaneously occurring immune re-
sponses in cancer patients strongly support the concept 
of immunosurveillance. Several MHC class I- and class 
II-restricted epitopes from NY-ESO-1, which are recog-
nized by CD8+ cytotoxic and CD4+ helper T cells, re-
spectively  [27, 28] , have been characterized. These in-
clude epitopes restricted by MHC molecules that are rel-
atively common in the Caucasian population such as the 
MHC class I molecules HLA-A2, HLA-A24 and HLA-
B35, as well as the MHC class II molecules HLA-DR4 and 
HLA-DP4. These achievements are particularly impor-
tant because they facilitate the monitoring of vaccine-in-
duced and spontaneous immune responses in cancer pa-
tients.
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 The relevance of NY-ESO-1 as a tumor antigen is illus-
trated by observations we made recently on a 61-year-old 
male patient who was diagnosed with metastatic mela-
noma with an unknown primary in March 2001 (ZH-311). 
The involved inguinal mass was widely excised and ex-
pressed NY-ESO-1. Upon immunization with recombi-
nant fowlpox virus (rFV)/NY-ESO-1 in March 2004, his 
liver and lymph node metastases significantly decreased 
and no further lesions developed initially. However, in 
March 2005 he developed a single brain metastasis, which 
was resected, and NY-ESO-1 – . Because the primary tumor 
was never detected, the interpretation is that it was con-
trolled and eventually eliminated by the spontaneous
NY-ESO-1-specific immunity, an example of effective im-
mune surveillance in vivo. The patient responded to rFV/
NY-ESO-1 immunization with increased humoral and 
cellular immunity against NY-ESO-1, which was presum-
ably responsible for the initial control and remission of 
disease. We assume that the subsequent NY-ESO-1 – me-
tastases developed as a result of immunological pressure 
and can be seen as an example of immunoediting.
 Immunotherapy as an Integrated Approach in 
Cancer Treatment 
 After two decades of immunotherapy in preclinical 
models for cancer and patients, it is clear that significant 
hurdles, which prevent the induction of sustained tumor-
specific effector functions in cancer patients, exist. The 
major aim for cancer immunotherapy is to identify these 
hurdles and to design treatments to circumvent these. 
The field of immunoregulation has made great progress 
during the last years, and many of the cells and factors 
involved in immunoregulation seem to impinge on tu-
mor-specific immunity as well. First, tumor-specific T 
cells may be unable to infiltrate the tumor. Second, tumor 
antigens may be (ectopically) expressed in the thymus, 
which may purge the repertoire of tumor-specific T cells 
from high-avidity clones. Third, tumor-derived antigens 
are presumably presented to naïve T cells by steady-state 
dendritic cells, which may result in robust peripheral T 
cell tolerance. Fourth, chronic presentation of antigen 
may functionally or physically exhaust specific effector 
cells. Fifth, regulatory T cells in the tumor microenviron-
ment block local T cell function or block the priming of 
tumor-specific T cells. Finally, the tumor environment 
may produce soluble factors, such as IL-10 and TGF-  , or 
promote the presence of myeloid-derived suppressor 
cells, all of which locally suppress T cell effector function.
 The ultimate goal of cancer immunotherapy is to im-
munize patients with a tumor-associated antigen togeth-
er with an adjuvant to stimulate innate immune defense. 
Because the immune system evolved to combat patho-
gens, immunization under conditions that mimic an in-
fection is considered to be crucial for the induction of 
protective immunity. Compared to prophylactic vaccina-
tion, where an immune response is induced with a for-
eign antigen, therapeutic vaccination has proven to be 
more demanding. It is thought that prolonged antigen 
presentation under noninflammatory conditions, which 
may occur during persistent viral infections such as HBV 
or HIV or in cancer patients, results in subversion of the 
immune response by (partial) tolerization or exhaustion 
of specific T cells. Thus, besides an immunogenic antigen 
and an adjuvant, the vaccine presumably must contain a 
treatment modality that interferes with ongoing immu-
noregulation in order to be effective in cancer patients.
 At present, clinical trials are under way that integrate 
the issues discussed above. For instance, treatment with 
antibodies that block CTLA-4 or PD-1 have resulted in 
objective clinical responses in some patients. It may be 
worth designing trials that combine both antibodies, as 
there is evidence that both regulatory pathways are non-
redundant. It is only recently that trials have started in 
which blockade of CTLA-4 or PD-1 is combined with ac-
tive immunization or with active immunization plus pre-
ceding lymphodepletion. The latter approach may be 
promising, as lymphodepletion removes many regulatory 
0 10 20 30 40 50
Expression of NY-ESO-1 (%)
Melanoma
NSCLC
SCLC
Urothelial
Breast
Ovarian
Sarcoma
Prostate
Gastric
 Fig. 1. NY-ESO-1 expression in various types of cancer. The per-
centages of different tumors positive for NY-ESO-1 were derived 
from at least 300 independent biopsies that were analyzed by im-
munohistochemistry. A tumor was considered positive when  1 5% 
of the cells were stained. 
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cells from the patients before the new thymic emigrant T 
cells are confronted with the vaccine.
 In addition to vaccination with recombinant patho-
gens, recombinant proteins or (long) peptides in order to 
induce an integrated (antibodies and T cells) and tumor-
specific immune response, the therapeutic potential of 
antibodies against tumor-associated, intracellular anti-
gens is being investigated. To this end, we generated a 
fully human monoclonal IgG that recognizes NY-ESO-1. 
We cloned the B cell receptor (IgG) from EBV-trans-
formed B cells of a cancer patient with high titers of spon-
taneous IgG against NY-ESO-1 and produced the human 
monoclonal IgG as a recombinant protein. The advantage 
of this approach is that we generate antibodies that are 
biologically relevant and probably safe, as they were de-
rived directly from patients. We propose that high levels 
of NY-ESO-1-specific IgG will localize to otherwise dam-
aged tumor tissues and form immune complexes with 
NY-ESO-1 that is released from apoptotic or necrotic tu-
mors. Those immune complexes will subsequently be 
taken up efficiently by dendritic cells for antigen presen-
tation to NY-ESO-1-specific T cells. Cell death or necrosis 
of tumors, and thus presumably the therapeutic effect of 
antibodies, can be enhanced by radiotherapy, chemo-
therapy or other tumoricidal interventions. At present, 
patient-derived cancer-specific antibodies are highly 
promising agents for the initiation of an integrated tu-
mor-specific immune response in cancer patients in the 
context of multimodal treatment approaches to combat 
cancer.
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